Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry.
cardiogenic shock
guideline‐directed medical therapy
heart failure
left ventricular ejection fraction
mortality
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
medline:
11
3
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
ppublish
Résumé
The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline-directed heart failure (HF) medical therapy (GDMT) and one-year survival rate in patients who are post-CS. FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in-hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, In survivors of CS, the one-year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.
Sections du résumé
BACKGROUND
BACKGROUND
The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline-directed heart failure (HF) medical therapy (GDMT) and one-year survival rate in patients who are post-CS.
METHODS AND RESULTS
RESULTS
FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in-hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%,
CONCLUSIONS
CONCLUSIONS
In survivors of CS, the one-year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.
Identifiants
pubmed: 38390813
doi: 10.1161/JAHA.123.030975
pmc: PMC10944045
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin Receptor Antagonists
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e030975Références
Circ Heart Fail. 2008 May;1(1):34-42
pubmed: 19808268
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2015 Feb;17(2):159-68
pubmed: 25808849
Eur J Heart Fail. 2022 Nov;24(11):2152-2161
pubmed: 35791663
Circulation. 2019 Jan 15;139(3):337-346
pubmed: 30586728
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Lancet. 2013 Nov 16;382(9905):1638-45
pubmed: 24011548
Am J Epidemiol. 2023 Jun 2;192(6):987-994
pubmed: 36790803
Open Forum Infect Dis. 2022 Mar 07;9(4):ofac110
pubmed: 35355895
Circ J. 2021 Sep 24;85(10):1823-1831
pubmed: 33828028
Cardiovasc Diabetol. 2019 Feb 7;18(1):16
pubmed: 30732594
J Am Heart Assoc. 2014 Jan 13;3(1):e000590
pubmed: 24419737
Vascul Pharmacol. 2022 Oct;146:107095
pubmed: 35944842
ESC Heart Fail. 2022 Feb;9(1):408-419
pubmed: 34973047
JACC Heart Fail. 2020 Sep;8(9):725-738
pubmed: 32800509
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
ESC Heart Fail. 2021 Aug;8(4):3308-3315
pubmed: 34145983
Lancet. 2019 Jan 5;393(10166):61-73
pubmed: 30429050
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
Circ J. 2016;80(4):852-9
pubmed: 27001192
Eur J Heart Fail. 2014 Sep;16(9):1009-15
pubmed: 25044535
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Lancet. 2022 Dec 3;400(10367):1938-1952
pubmed: 36356631
Arch Cardiovasc Dis. 2019 May;112(5):343-353
pubmed: 30982720
Am Heart J. 2019 Jul;213:18-29
pubmed: 31078113
Eur J Heart Fail. 2017 Oct;19(10):1242-1254
pubmed: 28463462
Eur Heart J. 2019 Aug 21;40(32):2671-2683
pubmed: 31274157
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
J Am Coll Cardiol. 2022 Mar 8;79(9):933-946
pubmed: 35115207
J Am Heart Assoc. 2020 Aug 18;9(16):e015042
pubmed: 32805181
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
J Heart Lung Transplant. 2013 Jan;32(1):106-11
pubmed: 23260710
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Circ Heart Fail. 2016 Jul;9(7):
pubmed: 27413037
Eur J Heart Fail. 2020 Aug;22(8):1315-1341
pubmed: 32469155
Circ Heart Fail. 2021 Jun;14(6):e008141
pubmed: 34129366
EuroIntervention. 2018 Jun 08;14(3):e306-e313
pubmed: 29205158
J Am Coll Cardiol. 2016 Feb 23;67(7):739-47
pubmed: 26892407